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Phosphorus and protein restriction and parathyroid function in
chronic renal failure. Phosphorus retention as a result of chronic renal
failure (CRF) induces secondary hyperparathyroidism (HPT II) while
supplemented low-phosphorus low-protein diets (LPD) prevent it. The
aim of this study was to assess in seven patients with advanced CRF and
biological HPT lithe effects of a LPD providing daily 5 to 7 mg/kg
phosphorus, 0.4 g/kg protein, 300mg calcium (Ca) and supplemented with
amino acids, ketoacids, CaCO3 and vitamin D2, on the relationship
between ionized Ca (iCa) and PTH concentrations. Hyper- and hypocal-
cemia were induced by CaCI2 and Na2-EDTA infusion. After three
months of LPD, serum phosphorus decreased from 1.59 0.15 to 1.26
0.24 mmol/liter (mean SEM, P < 0.02), basal PTH levels from 251 25
to 127 16 pg/mI (P < 0.03), while basal iCa and GFR did not vary. The
sigmoidal PTh-calcium curve shifted downward with maximal PTH
decreased from 482 86 to 319 60 pg/ml (P < 0.02) and minimal PTH
from 35 4 to 21 4 pg/mI (P < 0.05). On the other hand, the slope of
the % maximal PTH-iCa curve, which is an indicator of the sensitivity of
the parathyroid cell to changes in iCa concentrations, did not vary
significantly. The set point of Ca and calcitriol levels were not modified.
These results demonstrate a direct inhibition of PTH secretion over a wide
range of iCa concentration by LPD in patients with advanced CRF and
mild HPT II over a three months period. This effect is independent of
changes in plasma calcitriol levels.
Resistance to the calcemic action of parathormone (PTH) and
decreased sensitivity of parathyroid cells to hypercalcemia con-
tribute to the development of secondary hyperparathyroidism in
chronic renal failure [1, 2]. Low calcitriol levels, phosphate
retention and down-regulation of bone cell receptors for PTH [1,
3] are the most important of the mechanisms postulated to be
responsible for the resistance to the calcemic action of PTH, but
their respective contributions are still unclear. Dynamic evalua-
tion of parathyroid function by the sigmoidal PTH-calcium curve
developed during hypo- and hypercalcemia in uremic patients
with secondary hyperparathyroidism has shown that basal, maxi-
mal and minimal PTH levels are higher than in normal individu-
als. In uremic patients with histologically proven osteitis fibrosa
compared to patients with other forms of renal osteodystrophy,
maximal stimulation of PTH secretion and the set point of
calcium for PTH are observed at higher serum ionized calcium
(iCa) concentrations and the slope of the linear part of the
sigmoidal curve is increased, the sigmoidal curve being shifted to
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the right and upward [2]. These findings could be related to
increased parathyroid cell mass and increased sensitivity of para-
thyroid cells to hypocalcemia in this group of patients [2].
In 1984, Slatopolsky et al [4] demonstrated that intermittent
intravenous calcitriol could suppress PTH secretion effectively in
patients on regular dialysis therapy. Since then, several studies of
chronic hemodialysis patients with secondary hyperparathyroid-
ism have confirmed these results, showing similar effects with
intravenous and oral calcitriol pulse therapy [2, 5—9]. The study of
the sigmoidal PTH-calcium curve before and after calcitriol
therapy demonstrated a decrease in PTH secretion across a wide
range of iCa concentrations, and a decrease in the slope of the
linear part of the curve. These results were in accordance with the
extensively demonstrated suppressive effect of calcitriol on PTH
synthesis and secretion [1, 21 and were evidence for reduced
sensitivity of parathyroid cells to hypocalcemia after calcitriol
treatment [2]. However, the effects of calcitriol treatment on
parathyroid function could be blunted if a satisfactory control of
phosphate concentration were not obtained [6], emphasizing the
role of phosphate in PTH metabolism.
In previous studies [10, 11] we have shown that in patients with
advanced renal failure, secondary hyperparathyroidism might be
controlled by a phosphorus- and protein-restricted, calcium sup-
plemented diet, without any increase in plasma calcium and
calcitriol levels, in accordance with previous experimental studies
of the PTH-lowering effect of phosphorus restriction in azotemic
dogs [12], and of protein and phosphorus restriction in humans
[13]. We postulated that the suppression of hyperparathyroidism
was mainly due to the decrease in plasma phosphate, and to a
lesser extent to the correction of acidosis and the increase in
25-OH vitamin D, independent of changes in calcitriol concentra-
tions [11]. The present study was undertaken to assess the effect of
a low-phosphorus low-protein diet supplemented with amino
acids and ketoanalogs, calcium and vitamin D2, on parathyroid
gland function, in patients with advanced renal failure and
moderate secondary hyperparathyroidism.
Methods
Patients
Seven ambulatory patients with advanced chronic renal failure
(GFR 9.9 0.9 ml/min) and biochemical evidence of secondary
hyperparathyroidism (PTH > 150 pg!ml, normal < 60 pg/ml)
were selected for the study. Patients with diseases known to
interfere with calcium and phosphate metabolism were excluded.
None of the selected patients were taking steroids, anticonvulsant
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Table 1. Characteristics of the patients
Number of patients 7
Age years 50.9 7
Range 28—69
Male/Female 1/6
Underlying nephropathy
Chronic interstitial nephritis 4
Hereditary nephritis 1
Unknown 2
drugs, calcium supplements, calcitriol or any other vitamin D
analogs, aluminum-containing antacids or other phosphate bind-
ers. Table 1 summarizes the clinical characteristics of the patients.
Local Ethics Committee approval and patients' informed consent
were obtained for the study.
Diet
Before the study all patients were already on a somewhat
protein-restricted diet which was in every case greater than 0.8
g/kg/day. From dietary interviews calcium and phosphorus intakes
were respectively evaluated to be 650 85.1 mg/day and 860
84.3 mg/day. For the study, the patients received a diet (referred
to as LPD) providing 0.4 g/kg protein of vegetable origin, 5 to 7
mg/kg of inorganic phosphorus and 300 mg of calcium daily. The
prescribed caloric intake was 35 Kcal/kg/day supplied 67% by
carbohydrates, 30% by lipids and 3% by protein. The diet was
supplemented with tablets of essential amino acids and ketoana-
logues (Cetolog, Clintec, France). The composition of the tablets
has been described in detail elsewhere [141. The mean daily dose
was 1 tablet per 5 kg body weight, each tablet providing 75 mg
nitrogen and 3.4 mg calcium. Calcium was given in the form of
calcium carbonate at a dose of 400 to 800 mg/day of elemental
calcium to maintain serum calcium levels between 2.1 to 2.5
mmol/liter. All patients were also supplemented with iron and a
multivitamin preparation providing 1,000 I.U. of vitamin D2 per
day. The patients were followed over a three month period.
Compliance with the prescribed diet was assessed monthly by
interviews after a four-day food diary and by measurements of
urinary urea and phosphorus excretion. Protein intake was also
estimated by the formula of Maroni, Steinman and Mitch [15].
Patients were considered as compliant when protein intake esti-
mated by urinary measurements and dietary interviews was within
of prescribed protein intake [16].
Biochemical follow-up
Before the study and every month thereafter, the following
parameters were determined: 24-hour urinary creatinine, urea,
calcium, phosphate and fasting plasma creatinine, urea, calcium,
phosphate, bicarbonate, alkaline phosphatase, osteocalcin and
intact PTH.
Evaluation of parathyroid function
To evaluate parathyroid function, the suppressibility of para-
thyroid secretion was studied by raising calcium concentration
through intravenous calcium infusion while stimulation of the
parathyroids was studied by lowering calcium concentration using
infusion of a calcium-chelating agent. The effect of LPD on
parathyroid function was assessed after a three month period,
which was the period of time needed to reach a nadir in plasma
PTH levels in our previous study [10]. At baseline and after three
months on a LPD, the PTH secretion stimulation test was
performed three days after the calcium infusion test. From the
data obtained during hypocalcemia and hypercalcemia, individual
PTH-calcium curves were constructed for each patient at baseline
and after three months of LPD, according to Brown [17] and
Felsenfeld and Llach [2]. Composite PTH-calcium curves were
compiled from the individual curves at baseline and after three
months of LPD [2]. The terms used for the analysis of PTH-
calcium curves have been defined extensively in a recent review
[2]: maximal PTH represents maximal stimulation of parathyroid
glands, minimal PTH represents maximal inhibition of parathy-
roid, the set point of calcium is the ionized calcium concentration
which corresponds to 50% maximal PTH.
Calcium infusion test. Calcium chloride (CaCl2, 100 mg/mI) was
infused at a constant rate of 3 mg/kg body wt/hr of elemental
calcium [18] over a three hour period via a catheter inserted into
a peripheral vein. During the same three hour period 300 ml of
5% glucose were infused by the same catheter to dilute calcium
and avoid vein damage. Blood samples were withdrawn from the
contralateral arm at 0, 10, 20, 30, 60, 120 and 180 minutes after
beginning calcium infusion.
PTH secretion stimulation test. A total amount of 50 mg/kg body
wt of disodium ethylenediamine tetraacetate (Na2-EDTA, 50
mg/ml) diluted in 500 ml of 5% glucose was infused over a three
hour period via a catheter inserted into a peripheral vein [modi-
fied from 19]. Blood samples were withdrawn from the contralat-
eral arm at 0, 30, 60, 120, 150 and 180 minutes after beginning
Na2-EDTA infusion start.
Analytical methodology
Glomerular filtration rate (GFR) was evaluated at the begin-
ning and end of the study based upon the clearance of 51Cr EDTA
determined from plasma and urine samples [16]. Creatinine and
electrolyte determinations were performed using a Technicon
AutoAnalyzer. Ionized calcium was measured with a Coming
analyzer. Intact plasma PTH was measured using a two-site
radioimmunoassay [20]. At 0 and 3 months plasma osteocalcin
was assessed by radioimmunoassay [21] and plasma calcidiol and
calcitriol were measured by competitive binding assays [22, 23].
Statistical analysis
Data are presented as mean standard error. They were
analyzed using Statview II computer software (Abacus Concepts,
California, USA), analysis of variance (ANOVA) for repeated
measurements or Wilcoxon's rank test, as appropriate. A P value
less than 0.05 was considered significant.
Results
Clinical tolerance, compliance and renal function
All patients presented advanced chronic renal failure with GFR
between 6.7 and 14.6 ml/min. During the three month follow-up
their EDTA clearance remained unchanged: 9.9 0.9 to 9.9 1.9
mi/min. Their body weight remained stable (58.5 10.5 vs. 59.6
12.3 kg, NS), the mean serum albumin and protein levels were not
modified during the follow-up (Table 2). Satisfactory dietary
compliance in all patients was confirmed by significant decreases
in urinary urea and phosphate and in plasma urea concentration
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Table 2. Renal function and evaluation of compliance to low-protein
low-phosphorus diet
After
Before
LPD
3 months
LPD Significance
GFR mI/mm 9.9 0.9 9.9 1.9 NS
Serum urea mmol/ 21.5 2.3 11.6 0.7 <0.02
liter
Urinary urea 208 18 81 7 <0.01
mmol/24 hr
Serum creatinine 417 18 415 30 NS
pinol/liter
Urinary phosphate 13.4 1.7 5.5 1.5 <0.03
mmol/24 hr
Serum albumin 39,3 1.3 37.2 1.2 NS
giliter
Serum proteins 62.9 1.4 64.9 1.8 NS
giliter
Results are expressed as mean sE.
(Table 2), which were observed at the first monthly visit and
remained stable thereafter (data not shown).
Calcium and phosphate metabolism parameters
From Tables 3 and 4, it appears that, at the start of the study,
patients displayed characteristic abnormalities usually observed in
advanced chronic renal failure including raised phosphorus and
PTH plasma levels, increased alkaline phosphatase activity and
osteocalcin concentration, and calcium and calcitriol levels at the
lower level of the normal range.
As shown in Table 3, LPD corrected hyperphosphatemia and
lowered basal PTH levels from 251 25 to 127 16 pg/ml (P <
0.03) by the end of the study while serum ionized and total
calcium levels did not change significantly. Plasma calcitriol
remained at the lower end of the normal range, from 18.8 3.1
at baseline to 13.5 2 pg/mI after three months of LPD (NS).
Osteocalcin concentration and alkaline phosphatase activity were
not significantly modified by the diet. A non-significant trend
toward correction of acidosis was observed, with serum bicarbon-
ates rising from 20.3 1.8 to 24.0 1.0 mmol/liter.
PTH-calcium curve
In each patient, the lower plateau of PTH secretion was
reached by infusion of CaCI2, while the higher plateau was
reached by infusion of Na2-EDTA, these conditions being neces-
sary for the evaluation of parathyroid function [2]. In Figure 1A,
the composite PTH-calcium curves from the seven patients are
presented at baseline and after three months of LPD. At the start
of the study, basal, maximal and minimal PTH levels were
respectively at 251 25, 482 86 and 35 4 pg/mi. These values
are significantly higher than those reported in normal individuals
(respective values: 23.2 2.0; 99.9 14.5; 5.6 1 pg/mI [24])
while the set point was within the normal range: 1.14 0.02
mmol/liter (Table 4). After three months of LPD, lower PTH
levels (P < 0.01 by ANOVA for repeated measurements) were
observed when the whole range of calcium concentrations of the
curve was considered (Fig. 1A). However, individual points were
different between the two periods by Wilcoxon's rank test only for
ionized calcium concentrations ranging from 1.05 to 1.25 mmol/
liter. The maximum P1'H response decreased after three months
Table 3. Evolution of parameters of phosphate and calcium
metabolism with LPD
After
Normal
range
Before
LPD
3 months
LPD Significance
Total calcium mmol/ 2.1—2.65 2.18 0.05 2.29 0.06 NS
liter
Serum phosphate 0.8—1.45 1.59 0.15 1.26 0.09 <0.02
mmoi/iiter
Serum bicarbonates 24—30 20.3 1.8 24.0 1.07 NS
mmol/liter
Basal PTH pg/mi 10—60 251± 25 127± 16 <0.03
Calcitriol pg/ml 12—32 18.8 3.1 13.5 2.0 NS
Alkaline phosphatase 30—120 108 21 95 26 NS
lU/liter
Osteocalcin pg/mi 3.7—6.9 61 6 52 8 NS
Results are expressed as mean SE.
of dietary treatment from 482 16 to 319 60 pg/mi (P < 0.02)
with a ratio of basal to maximal PTH declining from 56 6 to 44
6 (P < 0.05). The minimal PTh response observed after the
calcium infusion test decreased from 35 4 to 21 4 pg/mi (P <
0.05). When the PTH-calcium curves were constructed with
maximal PTH level as 100% to factor for differences in absolute
PTH levels between the two periods of study [2], the slopes of the
curves were not significantly different: —556 105 to —365
54% mmol' liter (Fig. 1B). The set point of calcium did not
vary significantly after three months of LPD from 1.14 0.02 to
1.13 0.02 mmol/liter.
Discussion
In the present study, after three months of supplemented
low-phosphorus low-protein diet, PTH and serum phosphorus
decreased whereas total and ionized calcium and calcitriol levels
were not significantly modified, in accordance with our previous
findings [10, 11]. PTH levels were lower after three months of
LPD over a wide range of ionized calcium concentrations. How-
ever, neither the set point of calcium nor the slope of the curve
changed.
The PTH-calcium curves observed at the beginning of the study
were similar to the sparse data previously reported in undialyzed
patients with CRF [25, 26]. Maximal, basal and minimal PTH
levels which are all indicators of functional parathyroid gland
mass [27] were much higher than those reported by Brent et al
[24] in normal subjects. Minimal PTH level (nonsuppressible
component) was 7% of the maximal PTH in normal individuals.
This value is between 5 and 10% in our study. The basal to
maximal PTH ratio, which indicates the activity of the parathyroid
glands at baseline, was higher than in normal subjects (56% vs.
23%) suggesting that the elevated basal PTH production was at
the expense of a relatively reduced secretory reserve. In an earlier
study Llach et al [25] estimated the basal to maximal PTH ratio to
be 30% in patients with early renal failure (creatinine clearance 65
5 mI/mm), whereas the maximal PTH value was 2.5 times
greater than in normal subjects. In another study [26] the same
authors reported in 12 patients with a similar degree of renal
failure, a basal to maximal PTH ratio of 50% and a maximal PTH
value only 1.3 times greater than in normal individuals. However,
studies in patients with CRF were performed using a carboxy-
terminal PTH assay [25, 26], while plasma intact PTH levels were
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Fig. 1. Composite PTH-calcium curves
demonstrating the effect of low-phosphorus, low-
protein diet on PTH secretion during hypo- and
hypercalcemia in all patients, Results are
presented as mean SE. A. PTH-calcium curve
at baseline (•) and after three months of
supplemented low-phosphorus, low-protein diet
(0). *Significant differences between periods by
Wilcoxon's rank test. 13. PTH-calcium curves
with maximal PTH transformed to 100%, at
baseline (•), and after three months of
supplemented low-phosphorus, low-protein diet(0). No significant differences in the slope of
the % maximal PTH-iCa curves were observed.
Table 4. Evolution of parameters of the PTH-calcium curve before and
after 3 months of low-phosphorus, low-protein diet
Alter
Before
LPD
3 months
LPD Significance
Basal PTHpg/ml 251 25 127 16 <0.03
Maximal F'FHpg/ml 482 86 319 60 <0.02
Minimal PTH pg/mI 35 4 21 4 <0.05
Basal/maximal PTH % 56 6 44 6 <0.05
Set point of calcium 1.14 0.02 1.13 0.02 MS
mmol/liter
Basal ionized calcium 1.11 0.03 1.16 0.04 MS
mmol/liter
Relative slope of PTI-1- —556 105 —365 54 MS
calcium curve
mmot1 liter
measured in the studies in normal subjects [24], which may have
increased the differences in PTH levels. In dialysis patients with
marked osteitis fibrosa, Felsenfeld et al found markedly elevated
basal PTH levels, with a 61% ratio of basal to maximal PTH,
compared to values close to 35% in other forms of renal osteodys-
trophy [28]. Rodriguez et al [6] and Malberti, Surian and Cosci [8]
have reported similar results in dialysis patients, with basal to
maximal PTH ratios of respectively 72% and 62.8%. Although the
degree of secondary hyperparathyroidism, as judged by serum
PTH levels, was much less pronounced in our patients than in
these studies, their high basal to maximal PTH ratios at baseline
are indicative of high stimulation of PTH. In a previous study of
17 patients with similar degrees of renal failure and of biological
hyperparathyroidism, we found evidence of osteitis fibrosa in nine
patients, mixed osteopathy (osteomalacia associated with osteitis
fibrosa) in four patients, and only four patients with normal bone
remodelling [10].
The mean initial set point was 1.14 0.02 mmol/liter. This
value is close to the set point of normal individuals: 1.15 to 1.20
mmol/liter [17] and similar to those observed by Dunlay et al [5]
and Rodriguez et al [6] in dialysis patients. In chronic hemodial-
ysis patients the set point has been reported to vary according to
the type of renal osteodystrophy, higher values being observed in
patients with marked osteitis fibrosa than in patients with other
forms of renal osteodystrophy [2, 28]. However, as in the present
study, the set point of calcium is not different between patients
with secondary hyperparathyroidism and normal volunteers [2].
After three months of LPD, baseline PTH declined by 47
10% without significant change in iCa or calcitriol levels. Plasma
bicarbonate levels tended to increase, although not significantly.
In other studies involving greater numbers of patients, uremic
acidosis was significantly corrected by LPD due to the low acid ash
of the diet [10, 16] and calcium carbonate supplementation. Both
minimal and maximal PTH levels were reduced, suggesting a
reduced PTH production per parathyroid cell and/or a reduction
of the number of parathyroid cells [2]. Yi, Fukagawa and Kuro-
kawa have recently shown [29] that mild phosphorus restriction
could normalize synthesis and secretion of PTH and prevent
parathyroid cell proliferation in CRF rats. Basal PTH levels were
markedly depressed and the basal to maximal ratios decreased
significantly. The slope of the PTH-calcium curve did not vary
significantly, nor did the set point of calcium, suggesting that the
serum calcium concentration at which PTH secretion was stimu-
lated did not change [2, 6].
Calcitriol deficiency and phosphorus retention are major fac-
tors involved in the pathogenesis of secondary hyperparathyroid-
ism in patients with CRF. Since 1984 numerous studies have
confirmed, principally in dialyzed patients, the beneficial effects of
calcitriol therapy on secondary hyperparathyroidism [30], PTH
synthesis being modulated by calcitriol at the transcriptional level
[31, 32]. The evolution of the PTH-calcium curve in uremic
patients on calcitriol therapy has confirmed the direct suppressive
effect of calcitriol on PTH secretion, which is observed without
any increase in baseline serum calcium concentration. Dunlay et
al [5] observed, in nine hemodialysis patients receiving 2 jxg of
intravenous calcitriol after each dialysis for a ten week period, a
decrease in maximal and minimal PTH levels and in the slope of
the PTH-calcium curve without any modification of the set point
of calcium. Several studies have confirmed these results [7, 8, 18].
The evolution of parathyroid function observed in our CRF
undialyzed patients on LPD is very similar to the evolution
reported in patients on calcitriol therapy, with decreases in basal,
maximal and minimal Pill-I levels, and no significant changes in
the slope of the % maximal PTH-calcium curve. However, the
variations observed in our study were lower than in the dialysis
patients treated by calcitriol, since hyperparathyroidism was
milder in our predialysis patients. Furthermore, it is unlikely that
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the suppressive effect of LPD on PTH secretion observed in our
patients is exerted through a mechanism involving calcitriol
synthesis. In mild or moderate chronic renal failure, clinical
[33—35] and experimental [36] studies have shown that phospho-
rus restriction increases calcitriol serum levels, in relation with the
enhancement of 1-a-hydroxylase activity. In contrast, in advanced
chronic renal failure, the suppressive effect of phosphorus restric-
tion on secondasy hyperparathyroidism is observed, both in
humans [10, 11, 13] and animals [12, 36], independently of any
changes in calcitriol serum levels. Presumably, in advanced renal
failure calcitriol production already maximally stimulated by the
elevated basal PTH cannot further increase, because of reduced
functional renal mass. Another factor affecting calcitriol metabo-
lism in uremic patients is a decrease in the density of parathyroid
cell vitamin D receptors [37, 38]. It may be speculated that
although calcitriol levels remained unchanged throughout the
study, the lower retention of nitrogenous waste products reflected
by the decrease in plasma urea concentration may have increased
the number of parathyroid cell receptors to vitamin D and
indirectly influenced PTH secretion.
Phosphorus retention is another crucial factor involved in the
development of secondary hyperparathyroidism, PTH secretion
being stimulated by a high phosphorus intake and inhibited by a
reduced phosphorus intake [1, 2, 30, 39]. In the present study,
urinary phosphorus excretion was reduced by 59%, reflecting the
decrease in phosphorus intake, and the utilization of calcium
carbonate, a potent phosphate binder [30]. Phosphorus retention
may affect bone sensitivity to the calcemic action of PTH, which
may contribute to the development of secondary hyperparathy-
roidism. Somerville and Kaye [40] have shown, in a model of
isolated perfused rat tail, that an increase in inorganic phosphorus
concentration of the perfusate inhibited calcium release from
bone, while conversely, removal of phosphorus restored the
calcemic response to PTH. Rodriguez et al [36] have shown in rats
with CRF that differences in phosphorus intake resulted in
significant changes in the calcemic response to PTH infusion,
dietary phosphorus restriction during the PTH infusion inducing a
higher increase in serum calcium and a greater decrease in serum
phosphorus concentrations. But the mechanisms of this improved
response to PTH infusion were different according to the degree
of renal failure: calcitriol-dependent in normal rats and in rats
with moderate renal failure, calcitriol-independent in animals
with advanced renal failure. Lopez-Hilker et al [12] have demon-
strated in experimental studies that variations in phosphorus
intake modulate PTH secretion by a calcium- and calcitriol-
independent mechanism. The results of their study and of the
present one do not establish whether phosphorus restriction has a
direct effect on PTH transcription or a post-transcriptional effect
[12]. Nevertheless, even in patients on calcitriol therapy a reason-
able control of serum phosphate is necessary to permit its
efficacity upon secondary hyperparathyroidism [6].
The mild increase in calcium intake provided by LPD through
calcium carbonate supplementation may have contributed to
lower PTH secretion, in decreasing PTH synthesis at the tran-
scriptional level [41]. However, in rats with advanced renal failure,
a high calcium diet does not prevent the development of second-
ary hyperparathyroidism, because of further inhibition of calcitriol
synthesis [39]. In our study, it is unlikely that the increase in
calcium intake provided by LPD was a major contributing factor
in the inhibition of PTH secretion.
Other factors could be involved in the suppressive effect of LPD
on PTH secretion. Metabolic acidosis directly stimulates PTH
secretion independent of changes in ionized calcium or calcitriol
[42], and may worsen osteitis fibrosa [43]. The tendency toward
correction of acidosis that we have observed may have contributed
to the changes in parathyroid function induced by LPD [10].
However, we observed no correlation between variations in
plasma bicarbonate levels and basal plasma PTH concentration.
Uremia induces resistance to peptide hormones such as insulin
[44]. Just as LPD reduces the insulin resistance of uremia [45], a
similar action upon tissue sensitivity to PTH might exist.
Finally, the mixture of essential amino acids and ketoanalogs
provided by the diet could interfere with phosphorus metabolism
(and hence with PTH secretion) in two ways. First, calcium salts of
ketoanalogs have been shown by Schaeffer et alto effectively bind
phosphate [46]. However, it is unlikely that the ketoacids used for
supplementation in the present study influence intestinal phos-
phorus absorption, since they are in the form of ornithine salts
[14]. Second, it has been suggested that because of their anabolic
effect, essential amino acids could favor the incorporation of
phosphate into intracellular structures, leading to lower serum
phosphorus levels [47], but such an effect remains speculative.
In summary, in undialyzed patients with advanced chronic renal
failure, LPD ameliorates secondary hyperparathyroidism by di-
rectly inhibiting PTH secretion, probably through phosphorus
restriction, independently of calcitriol. LPD produces a decrease
in both minimal and maximal PTH levels and the sigmoidal
PTH-calcium curve is shifted downward. The set point of calcium
and the slope of the curve do not change. Parathyroid glands in
moderate hyperparathyroidism might be more sensitive to the
suppressant effect of LPD than those with the high secretory rates
observed in patients on regular dialysis therapy. However, even
more severe cases of secondary hyperparathyroidism require
phosphorus restriction in association with calcitriol therapy to
counteract PTH production.
Reprint requests to Prof esseur M. Aparicio, Service de Néphrologie, Hôpital
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References
1. FEINFELD DA, SIRwooD LM: Parathyroid hormone and
1,25(OH)2D3 in chronic renal failure. Kidney mt 33:1049—1058, 1988
2. FELSENFELD AJ, LLACH F: Parathyroid gland function in chronic renal
failure. Kidney mt 43:771—789, 1993
3. Gcuiw' T, MARTIN K, MORRISSEY JJ, SLATOPOLSKY E: Role of 1,25
dihydroxyvitamin D on the skeletal resistance to parathyroid hor-
mone. Kidney mt 37:801—807, 1987
4. Sixropoi.sicy E, WEERTS C, TnEI J, HORST R, HARTER H,
MARTIN K: Marked suppression of secondary hyperparathyroidism by
intravenous administration of 1,25 dihydroxycholecalciferol in uremic
patients. J C/in Invest 74:2136—2143, 1984
5. DUNLAY R, RODRIGUEZ M, FELSENFELD AJ, LLACH F: Direct inhibi-
tory effect of calcitriol on parathyroid function (sigmoidal curve) in
dialysis. Kidney mt 36:1093—1098, 1989
6. RODRIGUEZ M, FELSENFELD AJ, WILLIAMS C, PEDERSON JA, LLACH F:
The effect of long-term intravenous calcitriol administration on para-
thyroid function in hemodialysis patients. JAm Soc Nephrol 2:1014—
1020, 1991
7. Kw JTC, ALMOND MK, BEER JC, NOONAN K, EvANs SJW,
CUNNINGHAM J: "Pulse" oral calcitriol in uremic patients: Rapid
modification of parathyroid response to calcium. Nephrol Dial Trans-
plant 7:829—834, 1992
8. MALBERTI F, SURIAN M, Cosci P: Effect of chronic intravenous
calcitriol on parathyroid function and set point of calcium in dialysis
1386 Combe and Aparicio: Phosphorus-protein restriction and PTH in CRF
patients with refractory secondary hyperparathyroidism. Nephrol Dial
Transplant 7:822—828, 1992
9. RITZ E, SzAao A, REICHEL H: Parathyroidectoniy in secondary
(renal) hyperparathyroidism: Whom, when, how ? mt j Artif Organs
16:7—10, 1993
10. LAFAGE MH, CoMaE C, FOURNIER A, APARIci0 M: Ketodiet, physi-
ological calcium intake and native vitamin D improve renal osteodys-
trophy. Kidney mt 42:1217—1225, 1992
11. APARICIO M, COMaE C, LAFAGE MH, DE PRECI000T V, POTAUX L,
BOUCHET JL: In advanced renal failure, dietary phosphorus restriction
reverses hyperparathyroidism independent of changes in the levels of
calcitriol. Nephron 63:122—123, 1993
12. LOPEZ-HILKER 5, Dusso AS, RASP NS, MARTIN KS, SLATOPOLSKY B:
Phosphorus restriction reverses hyperparathyroidism in uremia inde-
pendent of changes in calcium and calcitriol, Am J Physiol 259:F432—
F437, 1990
13. LucAs PA, BROWN RE, WOODHERS JS, C0LE5 GA: 1.25 dihydroxy-
cholecalciferol and parathyroid hormone in advanced chronic renal
failure: Effects of simultaneous protein and phosphorus restriction.
C/in Nephrol 25:7—10, 1986
14. JANN H, ROSE F, SCHMITr R, MELIN G, ScHol-mi D, COMTE G,
SCHAETZEL 5: Protein synthesis in skeletal muscle of uremic patients:
Effect of low-protein diet and supplementation with ketoacids, Miner
Electrol Metab 18:222—227, 1992
15. MARONI BG, STEINMAN TI, MrrcH WE: A method for estimating
nitrogen intake in patients with chronic renal failure. Kidney mt
38:58—65, 1985
16. COMBE C, DEFORGES-LASSEUR C, Cix J, POMMEREAU A, MAItO'r D,
APARICIO M: Compliance and effects of nutritional treatment on
progression and metabolic disorders of chronic renal failure. Nephrol
Dial Transplant 8:412—418, 1993
17. BROWN EM: Four-parameter model of the sigmoidal relationship
between parathyroid hormone release and extracellular calcium con-
centration in normal and abnormal parathyroid tissue. J Clin Endo-
crinol Metab 56:572—581, 1983
18. DELMEZ JA, TINDIRA C, GROOMS P, DusSo A, WINDUS DW, SIA-
TOPOLSKY E: Parathyroid hormone suppression by intravenous 1,25-
dihydroxyvitamin D or increased sensitivity to calcium. J C/in Invest
83:1349—1355, 1989
19, GiutDm4 JP, PATRON P, FOUQUERAY B, PRIGENT A, PAILLARD M:
Maximal PTH secretory rate and set point for calcium in normal
subjects and patients with primary hyperparathyroidism. Miner Elec-
tro/Metab 14:221—228, 1988
20. NUSSBAUM SR, ZAHRADNIK RJ, LAYIGNE JR, BaneTAN GL, NozAwA-
UNG K, KIM LY, KENTMANN HT, WANG CA, Porrs if, SEGRE GV:
Highly sensitive two-site immunoradiometric assay of parathyrin, and
its clinical utility in evaluating patients with hyperealcemia. Clin Chem
33:1364—1367, 1988
21. DELMAS PD, STENNER D, WAHNER 1-1W, MANN KG, RIGGS BL:
Increase in serum bone gamma-carboxyglutamic acid protein with
aging in women, Implications for the mechanism of age-related bone
loss. J C/in Invest 71:1316—1321, 1983
22. PREECE MA, O'RIoIWAN JLH, LAWSON DE, KODICEK B: A compet-
itive binding assay for 25 OH cholecalciferol and 25 011 ergocalciferol
in serum. Clin Chem Acta 55:235—240, 1974
23. HOLLIS BW: Assay of circulating 1,25-dihydroxyvitamin D involving a
novel single-cartridge extraction and purification procedure. C/in
Chem 32:2060—2063, 1986
24. BRENT GA, LE Boru MS. SEEn' EW, CONLIN PR, BROWN EM:
Relationship between the concentration and rate of change of calcium
and serum intact parathyroid hormone levels in normal humans. J Clin
Endocrinol Metab 67:944—950, 1988
25. LLACH F, MASSRY 5G. SINGER FR, KUROKAWA K, K,vn JH, COBURN
JW: Skeletal resistance to endogenous parathyroid hormone in pa-
tients with early renal failure. A possible cause for secondary hyper-
parathyroidism. J Clin Endocrinol Metab 41:339—345, 1975
26. WILSON L, FELSENFELD A, DREZNER MK, LLACH F: Altered divalent
ion metabolism in early renal failure; Role of 1,25 (OH)2D. Kidney Int
27:566—573, 1985
27. Mc CARRON D, MUTFIER R, LENFESTY B, BENNE'IT W: Parathyroid
function in persistant hyperparathyroidism: Relationship to gland size.
Kidney Int 22:662—670, 1982
28. FELSENFELD A.!, RODRIGUEZ M, DUNLAY R, LIAcH F: A comparison
of parathyroid-gland function in haemodialysis patients with different
forms of renal osteodystrophy. Nephrol Dial Transplant 6:244—25 1,
1991
29. Yl 11, FUICAGAWA M, KUROKAWA K: Mild dietary phosphorus restric-
tion directly prevents enhanced parathyroid hormone secretion and
synthesis and proliferation of parathyroid cells in chronic renal failure.
(abstract) JAm Soc Nephrol 3:703, 1992
30. FOURNIER A, DRUEICE T, MORINIERE P, ZINGRAFF J, BOUDAILLEZ B,
ACHARD JM: Nouveaux traitements de l'hyperparathyroidie de
l'insuffisanee rénale, in Act Néphrol Hdpital Necker, Paris, Flam-
marion, 1991, pp 233—300
31. SILvER J, NAYEH-MANY T, MAYER H, SCHMELZER HJ, POPOvTZER
MM: Regulation by vitamin D metabolites of parathyroid hormone
gene transcription in vivo in the rat. J C/in Invest 78:1296—1301, 1986
32. NAvEH-MANY T, SILvER J: Regulation of parathyroid hormone gene
expression by hypoealeemia, hypercalcemia and vitamin D in the rat.
J C/in Invest 86:1313—1319, 1990
33. LLACH F, MASSRY SG: On the mechanism of secondary hyperpara-
thyroidism in moderate renal insufficiency. J C/in Endocrinol Metab
61:601—606, 1985
34. PORTALE AA, Boom BE, HAU.oRAN BE, MORRIS RE: Effect of
dietary phosphorus on circulating concentrations of 1.25-dihydroxyvi-
tamin D in children with moderate renal insufficiency. J C/in Invest
73:1580—1589, 1984
35. TE5SITORE N, VENTURI A, ADAMI 5, RONCARI C, RUGIA C, CORGNATI
A, BONUCCI B, MASCHIO G: Relationship between serum vitamin D
metabolites and dietary intake of phosphate in patients with early
renal failure. Miner E/ectro/ Mactb 13:38—44, 1987
36. RODRIGUEZ M, MARTIN-MAW A, MARTINEZ ME, TORRES A, FELSEN-
FEW A.!, LLACH F: Caleemic response to parathyroid hormone in
renal failure: Role of phosphorus and its effect on caleitriol. Kidney mnt
40:1055—1062, 1991
37. KORKOR AB: Reduced binding of [H3]1,25-dihydroxyvitamin D3 in the
parathyroid glands of patients with renal failure, N Eng/ J Med
316:1573—1577, 1987
38. MEm J, HUGEL U, ZLOTKOWSKI A, Sz.&ao A, BOMMER J, MALL G,
RITZ E: Diminished parathyroid 1,25-(011)2D3 receptor in experi-
mental uremia. Kidney mnt 32:350—353, 1987
39. BOvER J, RODRIGUEZ M, ThmnDft.r P, JARA A, MARTINEZ ME,
MACHADO L, LLACH F, FELSENFELD AJ: Factors in the development of
secondary hyperparathyroidism during graded renal failure in the rat.
Kidney mt 45:953—961, 1994
40. SOMERVILLE PJ, KAYE M: Action of phosphorus on calcium release in
isolated perfused rat tails. Kidney Int 22:348—354, 1982
41. YAMAMOTO M, IGARASHI T, MURAMATSU M, FUKAGAWA M, Mo-
TOKURA T, OGATA B: Hypoealcemia increases and hypercalcemia
decreases the steady state level of parathyroid hormone messenger
ribonucleic acid in the rat. J C/in Invest 83:1053—1056, 1989
42. BICFL&RA M, MERCIER 0, BORENSZTEIN P, PAILLARD M: Acute
metabolic acidosis enhances circulating parathyroid hormone, which
contributes to the renal response against acidosis in the rat. / C/in
Invest 86:430—443, 1990
43, LEFEBVRE A, DE VERNEJOUL MC, GUERIS J, GOLDFARa B: Optimal
correction of acidosis changes progression of dialysis osteodystrophy.
Kidney Int 36:1112—1118, 1989
44. DEFRONZO RA, ALVESTRAND A, SMITH D, HENDLER R: Insulin
resistance in uremia. / C/in Invest 67:563—568, 1981
45. GIN H, APARICIO M, POTAUX L, DE PRECIGOUT V, BOUCHET JL,
AUBERTIN J: Low-protein and low-phosphorus diet in palientS with
chronic renal failure: influence on glucose tolerance and tissue insulin
sensitivity. Metabo/ism 36:1080—1085, 1987
46. SCHAEFFER K, VON HERRATH 0, ASMUS G, UMLANG L: The beneficial
effect of ketoaeid on serum phosphate and parathyroid hormone in
patients with chronic uremia. C/in Nephro/ 30:93—96, 1988
47. HEIDLAND A, KULT J, RocL A, HEIDBRADER B: Evaluation of
essentials amino acids and keto acids in uremie patients on low protein
diets. Am / C/in Nub' 31:1784—1792, 1978
